Navigation Links
Viprinex in Medical News

Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results

...and to proceed expeditiously in the process," stated William Fletcher, acting Chief Executive Officer. Assuming accrued costs associated with the viprinex program are fully paid off by June 30, 2009 as currently estimated, the Company expects to end its fiscal year with approximately $23 million in cash,...

Neurobiological Technologies Reports Second Quarter Financial Results

...ently in two Phase III clinical trials. We believe viprinex has the potential to double the treatment window o...aZeneca's neuroprotectant drug candidate." About viprinex Phase 3 Trial Program viprinex is an investigational agent with multiple novel me...

Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ

...ng drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The company is currently developing viprinex (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. http://www.ntii.com A registrati...

Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke

...inex(TM) (ancrod), for the treatment of acute ischaemic stroke at the 16th annual European Stroke Congress in Glasgow, Scotland in the United Kingdom. viprinex is a defibrinogenating agent derived from the venom of the Malayan pit viper. "The ancrod data presented this week in Glasgow draws positive c...
Viprinex in Medical Technology

Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data

- Company Plans to Announce Interim Results in January 2009 and Final Trial Data in mid-2009 - EMERYVILLE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that following a meeting with the U.S. Food ...

Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)

Investigational Drug Being Pursued for the Treatment of Ischemic Stroke GLASGOW, Scotland, May 31, 2007 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI) announced today the presentation of new analysis of data from prior clinical trials of ancrod and updates on the clinical devel...

Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis

...an acute ischemic stroke, comparing treatment with viprinex to treatment with placebo. The DSMB determined tha...he study. "We are deeply disappointed that viprinex did not improve overall patient outcomes in our cl...adcount if we determine that future development of viprinex is not warranted." About Neurobiological T...

Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials

...coauthor of the retrospective analysis. "Earlier viprinex trials used a dosing regimen that infused the drug...urrently conducting two Phase 3 clinical trials of viprinex to investigate whether ancrod can safely and effec...have enrolled over 500 patients. NTI believes that viprinex can be administered up to six hours after the onse...

Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials

... interim analysis across the two studies. NTI is currently studying whether viprinex is safe and effective for treating acute ischemic stroke when given within ...as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to double th...

Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference

...rth American and European Phase 3 stroke trials of viprinex involving more than 1,700 patients. viprinex has been shown to rapidly reduce blood levels of f...enefit from this approach. "The prior studies of viprinex showed improved efficacy, but used a dosing regime...

Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)

...nctional outcome at 3 months. This is the fifth DSMB meeting for the Ancrod Stroke Program (ASP). The two trials are: -- ASP-I, the Study of Acute viprinex for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod in Subjects Beginning Treatment Within 6 Hours of the Ons...
Viprinex in Biological Technology

Neurobiological Technologies Announces Suspension of Viprinex Development

EMERYVILLE, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII ) (NTI(R)) today announced that, following a detailed analysis of the recent interim results of the Viprinex(TM) clinical trial, the company has decided not to develop Viprinex further for ...

Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program

EMERYVILLE, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today announced it will hold a conference call on Monday, October 13, to provide an update on the Viprinex(TM) (ancrod) Phase 3 Trial Program for acute ischemic stroke. Hosting t...

Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009

...l drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifica... sale of XERECEPT(R) by Celtic, the development of viprinex for acute ischemic stroke by NTI, delays or other ...blems with our clinical trials, the outcome of the viprinex interim analysis, the time and costs for obtaining...

Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results

...eiman, president and chief executive officer. "The viprinex studies have recently surpassed a total of 600 pat... will constitute a major go/no-go decision for the viprinex program, since it is the first efficacy assessment...ring Board (DSMB). For the trial to pass futility, viprinex must demonstrate predetermined efficacy criteria. ...

Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. NTI...

Neurobiological Technologies Sets Date for First Quarter Financial Results

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acu...

Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acu...

Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. NTI...

Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit

...d product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acu...

Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine

... advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acu...
Other Tags
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... Four years since the release of their debut ... the marriage of Avasa & Matthew Love – the duo are ... for release through White Swan Records on February 24, 2015. , ... sacred path available to all of us to walk out of ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
(Date:12/22/2014)...  NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" ... growing mobile commerce market, announces it has retained famous pickpocket, ... 2015 International CES debut of the Wocket™ biometric smart wallet.  ... the NXT-ID booth January 6th and 7 th , 2015, ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced the ... Security Systems Market" report to their offering. ... perimeter security market is estimated to grow at a CAGR ... holds a larger share in this market, Canada ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics Agency ... detect and prevent counterfeit microcircuits from entering into its ... an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. The ... increasing their reliability throughout the supply chain. The new ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
Other Contents